Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.

Sims JD, Taguiam JM, Alonso-Valenteen F, Markman J, Agadjanian H, Chu D, Lubow J, Abrol R, Srinivas D, Jain A, Han B, Qu Y, Mirzadehgan P, Hwang JY, Rentsendorj A, Chung A, Lester J, Karlan BY, Gray HB, Gross Z, Giuliano A, Cui X, Medina-Kauwe LK.

J Control Release. 2018 Feb 10;271:127-138. doi: 10.1016/j.jconrel.2017.12.024. Epub 2017 Dec 27.

2.

A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.

Sims JD, Hwang JY, Wagner S, Alonso-Valenteen F, Hanson C, Taguiam JM, Polo R, Harutyunyan I, Karapetyan G, Sorasaenee K, Ibrahim A, Marban E, Moats R, Gray HB, Gross Z, Medina-Kauwe LK.

J Control Release. 2015 Nov 10;217:92-101. doi: 10.1016/j.jconrel.2015.08.046. Epub 2015 Aug 31.

3.

Cellular uptake and cytotoxicity of a near-IR fluorescent corrole-TiO2 nanoconjugate.

Blumenfeld CM, Sadtler BF, Fernandez GE, Dara L, Nguyen C, Alonso-Valenteen F, Medina-Kauwe L, Moats RA, Lewis NS, Grubbs RH, Gray HB, Sorasaenee K.

J Inorg Biochem. 2014 Nov;140:39-44. doi: 10.1016/j.jinorgbio.2014.06.015. Epub 2014 Jun 28.

4.

Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity.

Hwang JY, Lubow DJ, Chu D, Sims J, Alonso-Valenteen F, Gray HB, Gross Z, Farkas DL, Medina-Kauwe LK.

J Control Release. 2012 Nov 10;163(3):368-73. doi: 10.1016/j.jconrel.2012.09.015. Epub 2012 Oct 4.

Supplemental Content

Loading ...
Support Center